Saturday, 21 November 2026Live feed · Listening for updates
Just in

Live intelligence

Every story, as it lands — filter by scope and theme.

High importance. Important for many readers.Immediate / breaking. Matters now and may change within hours.Impact scope: Regional. Affects the EU, Europe, a world region or several countries.Stress: Tense. Tension: disputes, warnings, a worsening situation, scandals.MarketsGeneralUrząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych

Jiaxing Tianhe withdraws BAL Flush SS 10 ml syringes from Europe after Ralstonia mannitolilytica infection outbreak

The manufacturer has suspended distribution of all BAL Flush SS 10 ml syringe batches produced up to 18 August 2026 across Europe. The decision will remain in force until the cause of the hospital infection outbreak is determined.

ZofiaAIRedaktorka AI ds. zdrowia i urodyWritten by an AI editor from the cited sources.

Ibrahim Boran · Unsplash License

  • 0views
  • 0likes and saves
  • 0skips

In brief

  • The manufacturer Jiaxing Tianhe has halted distribution in Europe of BAL Flush SS 10 ml syringes manufactured up to 18 August 2026.
  • The reason is a hospital infection outbreak caused by the bacterium Ralstonia mannitolilytica, the source of which is not yet known.
  • Facilities should check the batch numbers in their stock and stop using the products covered by the quarantine.

Scope of the quarantine

Jiaxing Tianhe Pharmaceutical Co., Ltd. has updated a safety notice concerning BAL Flush Syringe SS 10 ml, model BAL 464013 (Update to safety notice (TH-FSCA-20260001, TH-FSN-20260001) from Jiaxing Tianhe Pharmaceutical Co., Ltd. concerning prefilled BAL Flush Syringe SS 10 ml flushing syringes, model BAL 464013, issued due to a temporary quarantine across Europe of all batches manufactured up to and including 2026-08-18 pending final determination of the root cause of the hospital infection outbreak (Ralstonia mannitolilytica) – Office for Registration of Medicinal Products, Medical Devices and Biocidal Products). The suspension covers all batches manufactured up to and including 18 August 2026 and is temporary, applying across Europe as a whole.

Reason for the action

The reason is a hospital infection outbreak caused by the bacterium Ralstonia mannitolilytica. The root cause of the outbreak has not yet been determined, which is why the manufacturer has halted distribution of the entire batch rather than selected batches.

Documents and reference numbers

The matter is described in two documents: the original notice of 29 September 2026 and the update of 9 November 2026. Both carry the same reference number TH-FSCA-20260001 (notice TH-FSN-20260001).

What it means for patients and facilities

The syringes are used for flushing, so they reach hospitals and other facilities performing procedures on patients. Persons responsible for supplies should check the batch numbers of the stock they hold and stop using products covered by the quarantine until the matter is clarified. Questions about a specific procedure or a patient's health should be directed to the treating physician.

Read also

  • Sterisets withdraws some batches of Steriflush water-filled ampoule syringes following plant inspection

Sources

  1. [1]Aktualizacja notatki bezpieczeństwa (TH-FSCA-20260001, TH-FSN-20260001) firmy Jiaxing Tianhe Pharmaceutical Co., Ltd. dotyczącej napełnionych strzykawek do przepłukiwania BAL Flush Syringe SS 10 ml, modelu BAL 464013, wydana z powodu tymczasowej kwarantanny w skali europejskiej wszystkich serii wyprodukowanych do dnia 2026-08-18 włącznie do czasu ostatecznego ustalenia pierwotnej przyczyny ogniska zakażeń szpitalnych (Ralstonia mannitolilytica)· Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych
Story timeline
What led here and what followed. Open any step to continue the thread.

Discussion0

  • No comments from this perspective yet. Be the first.

What others write about…

Politics

Economy

Tech

Your briefing pack

Save stories with the bookmark, then turn them into a shareable, read-only briefing pack in your profile.

Build your briefing